Biofrontera (NASDAQ:BFRI) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Biofrontera (NASDAQ:BFRI) posted its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05, Zacks reports. The firm had revenue of $12.00 million during the quarter, compared to analyst estimates of $9.50 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%.

Here are the key takeaways from Biofrontera’s conference call:

• Q2 revenue rose 33% to $12.0 million, driven by approximately 30% Ameluz unit-volume growth and the 2025 price increase. Gross margin expanded to about 80%, while adjusted EBITDA improved to near breakeven from a $5.1 million loss a year earlier.
• Commercial momentum continued, with first-half order count up 18.6%, average tubes per order up 10%, and the installed base reaching approximately 801 lamps across 740 physician offices. Management said more than 81% of customers that made large pre-price-increase purchases reordered in the first half.
• The ITC exclusion order bars Biofrontera from importing or selling the current RhodoLED XL lamp and restricts Ameluz sales for use with that device. The company is pursuing an appeal and a minor lamp redesign, but must still obtain clearance from border authorities; approximately 243 XL lamps are affected.
• Biofrontera expects potential FDA approval for superficial basal cell carcinoma on September 28, 2026, with a planned first-quarter 2027 launch using its existing lamps and sales force. It also plans to file an expanded actinic keratosis indication by the end of the third quarter and is advancing an acne program toward Phase III.
• Liquidity remains a constraint, with $4.7 million in cash at June 30 and a going-concern qualification in the financial statements. Management expects to reach cash-flow breakeven in 2026 but may need a working-capital facility, while future clinical development depends on available funding.

Biofrontera Stock Performance

Biofrontera stock opened at $1.31 on Friday. The stock has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $0.98. The stock has a market capitalization of $16.83 million, a price-to-earnings ratio of -1.36 and a beta of 0.78. The company has a quick ratio of 1.09, a current ratio of 1.20 and a debt-to-equity ratio of 0.78. Biofrontera has a 12-month low of $0.55 and a 12-month high of $1.40.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Biofrontera to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Zacks Research raised Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biofrontera currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC grew its stake in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the period. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.